 |
|
A Pilot Study of Buspirone in Attention-Deficit Hyperactivity Disorder
Louis H. McCormick, MD;
Gaspard T. Rizzuto, PhD;
Hope B. Knuckles
Arch Fam Med. 1994;3(1):68-70.
References
Article references have been provided for searching and linking. Additional reference information may be available in the article PDF.
| |
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: The American Psychiatric Association; 1987:50-53.
2. Coleman WL, Levine MD. Attention deficits in adolescents: description, evaluation and management. Pediatr Rev. 1988;9:287-298.
FREE FULL TEXT
3. Barkley RA, Murphy JV. Treating attention-deficit hyperactivity disorder: medication and behavior management training. Pediatr Ann. 1991;20:256-266.
PUBMED
4. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD. Clinical effects of a controlled trial of methylphenidate on adolescents with attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1990;29:702-709.
PUBMED
5. Brown RT, Sexson SB. A controlled trial of methylphenidate in black adolescents. Clin Pediatr (Phila). 1988;27:74-81.
FREE FULL TEXT
6. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry. 1984;141:906-908.
FREE FULL TEXT
7. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD, I: efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
PUBMED
8. Cantwell DP. Pharmacotherapy of ADD in adolescence: what do we know, where should we go, how should we do it? Psychopharmacol Bull. 1985;21:251-257.
PUBMED
9. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebocrossover therapeutic trial. J Am Acad Child Adolesc Psychiatry. 1985;24:617-629.
10. Buspirone: a non-benzodiazepine for anxiety. Med Lett Drugs Ther. 1986;28:117-118.
PUBMED
11. Newton RE, Marunycz JD, Alderdice MT, Napoliello MJ. Review of the sideeffect profile of buspirone. Am J Med. 1986;80(suppl_3B):17S-21S.
12. Kranzler HR. Use of buspirone in an adolescent with overanxious disorder. J Am Acad Child Adolesc Psychiatry. 1988;27:789-790.
PUBMED
13. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J. 1990;83:194-198.
PUBMED
14. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry. 1989;50:382-384.
PUBMED
15. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122-125.
PUBMED
16. Quiason N, Ward D, Kitchen T. Buspirone for aggression. J Am Acad Child Adolesc Psychiatry. 1991;30:1026.
PUBMED
17. Balon R. Buspirone for attention deficit hyperactivity disorder? J Clin Psychopharmacol. 1990;10:77.
PUBMED
18. Conners CK. Rating scales for use in drug studies with children. Psychopharmacol Bull. 1973;9:24-84.
19. Werry JS. Measures in pediatric psychopharmacology. In: Werry JS, ed. Pediatric Psychopharmacology: The Use of Behavior Modifying Drugs in Children. New York, NY: Brunner Mazel; 1978:29-78. 20. Goyettte CH, Conners CK, Ulrich RF. Normative data on revised Conners' Parent and Teacher Rating scales. J Abnorm Child Psychol. 1978;6:221-236.
PUBMED
21. Wilson JM, Kiessling LS. What is measured by the Conners' Teacher Behavior Rating Scale: replication of factor analysis. J Dev Behav Pediatr. 1988;9:271-278.
PUBMED
22. Wallenstein S, Fisher AC. The analysis of the two-period repeated measurements crossover design with application to clinical trials. Biometrics. 1977;33:261-269.
PUBMED
23. Rostain AL. Attention deficit disorders in children and adolescents. Pediatr Clin North Am. 1991;38:607-633.
PUBMED
24. Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety: a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21:124-130.
PUBMED
25. Silver LB. Controversial approaches to treating learning disabilities and attention deficit disorder. AJDC. 1986;140:1045-1052.
PUBMED
26. Pelham WE, Greenslade KE, Vodde-Hamilton M, et al. Relative efficay of long-acting stimulants on children with attention deficit—hyperactivity disorder: a comparison of standard methylphenidate, sustained release methylphenidate, sustained release dextroamphetamine, and pemoline. Pediatrics. 1990;86:226-237.
FREE FULL TEXT
27. Kelly DP, Aylward GP. Attention deficits in school aged children and adolescents. Pediatr Clin North Am. 1992;39:487-513.
PUBMED
28. Eison AS, Temple DL. Buspirone: review of its pharmacology and current perspectives on its mechanism of action. Am J Med. 1986;80(suppl 3B):1S-9S.
29. Taylor DP, Becker JA, Crane M, Hyslop DK, Riblet LA, Temple DL. Chronic treatment with buspirone reduces type two serotonin binding sites. Soc Neurosci Abstr. 1983;9:435.
30. VanderMaelen CP, Wilderman RC. Iontophoretic and systemic administration of the non-benzodiazepine anxiolytic drug buspirone causes inhibition of serotonergic dorsal raphe neurons in rats. Federation Proc. 1984;43:947.
|
